An international clinical trial of a "special immunoglobulin preparation" made from human antibodies recovered from the new coronavirus has begun, and the National International Medical Research Center and others have participated in Japan to investigate the efficacy and safety of the drug by administering it to actual patients. I am.
This clinical trial is being promoted by an international framework funded by the National Institute of Allergy and Infectious Diseases in the United States, and the National Center for Global Health and Medicine and Fujita Medical University in Aichi Prefecture are participating from Japan.
"Special immunoglobulin preparation" is a drug that collects antibodies from people who have recovered from infection with the new coronavirus, and is expected to be effective against the new coronavirus.
According to the National Center for Global Health and Medicine, in collaboration with Fujita Medical University, the drug will be administered to 10 patients in Japan who are infected with the new coronavirus and need to be hospitalized, and the progress will be observed for about one month. , It means to investigate the effect and effectiveness together with the data from each country.
In addition, the National Center for Global Health and Medicine is currently conducting clinical research on "recovery hemorrhage treatment," in which an antibody-containing component called "blood gland" is extracted from the blood of a recovered person and administered. It is also to investigate whether there is a difference in safety and safety.
According to the National Center for Global Health and Medicine, "Effective treatments for the new coronavirus are limited, and if the efficacy and safety of this treatment are proven, it may become one of the effective treatments. ".